295 related articles for article (PubMed ID: 36335645)
1. Myosin Inhibition and Left Ventricular Diastolic Function in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Insights From the VALOR-HCM Study.
Cremer PC; Geske JB; Owens A; Jaber WA; Harb SC; Saberi S; Wang A; Sherrid M; Naidu SS; Schaff H; Smedira NG; Wang Q; Wolski K; Lampl KL; Sehnert AJ; Nissen SE; Desai MY
Circ Cardiovasc Imaging; 2022 Dec; 15(12):e014986. PubMed ID: 36335645
[TBL] [Abstract][Full Text] [Related]
2. Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks.
Desai MY; Owens A; Geske JB; Wolski K; Saberi S; Wang A; Sherrid M; Cremer PC; Naidu SS; Smedira NG; Schaff H; McErlean E; Sewell C; Balasubramanyam A; Lampl K; Sehnert AJ; Nissen SE
Circulation; 2023 Mar; 147(11):850-863. PubMed ID: 36335531
[TBL] [Abstract][Full Text] [Related]
3. Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy.
Hegde SM; Lester SJ; Solomon SD; Michels M; Elliott PM; Nagueh SF; Choudhury L; Zemanek D; Zwas DR; Jacoby D; Wang A; Ho CY; Li W; Sehnert AJ; Olivotto I; Abraham TP
J Am Coll Cardiol; 2021 Dec; 78(25):2518-2532. PubMed ID: 34915982
[TBL] [Abstract][Full Text] [Related]
4. Study Design and Rationale of EXPLORER-HCM: Evaluation of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy.
Ho CY; Olivotto I; Jacoby D; Lester SJ; Roe M; Wang A; Waldman CB; Zhang D; Sehnert AJ; Heitner SB
Circ Heart Fail; 2020 Jun; 13(6):e006853. PubMed ID: 32498620
[TBL] [Abstract][Full Text] [Related]
5. Effect of Mavacamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM.
Cresci S; Bach RG; Saberi S; Owens AT; Spertus JA; Hegde SM; Lakdawala NK; Nilles EK; Wojdyla DM; Sehnert AJ; Wang A
Circulation; 2024 Feb; 149(7):498-509. PubMed ID: 37961906
[TBL] [Abstract][Full Text] [Related]
6. Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy.
Desai MY; Wolski K; Owens A; Naidu SS; Geske JB; Smedira NG; Schaff H; Lampl K; McErlean E; Sewell C; Zhang D; Edelberg JM; Sehnert AJ; Nissen SE
Am Heart J; 2021 Sep; 239():80-89. PubMed ID: 34038706
[TBL] [Abstract][Full Text] [Related]
7. Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results From the VALOR-HCM Randomized Clinical Trial.
Desai MY; Owens A; Wolski K; Geske JB; Saberi S; Wang A; Sherrid M; Cremer PC; Lakdawala NK; Tower-Rader A; Fermin D; Naidu SS; Smedira NG; Schaff H; McErlean E; Sewell C; Mudarris L; Gong Z; Lampl K; Sehnert AJ; Nissen SE
JAMA Cardiol; 2023 Oct; 8(10):968-977. PubMed ID: 37639243
[TBL] [Abstract][Full Text] [Related]
8. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.
Olivotto I; Oreziak A; Barriales-Villa R; Abraham TP; Masri A; Garcia-Pavia P; Saberi S; Lakdawala NK; Wheeler MT; Owens A; Kubanek M; Wojakowski W; Jensen MK; Gimeno-Blanes J; Afshar K; Myers J; Hegde SM; Solomon SD; Sehnert AJ; Zhang D; Li W; Bhattacharya M; Edelberg JM; Waldman CB; Lester SJ; Wang A; Ho CY; Jacoby D;
Lancet; 2020 Sep; 396(10253):759-769. PubMed ID: 32871100
[TBL] [Abstract][Full Text] [Related]
9. Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy.
Desai MY; Owens A; Geske JB; Wolski K; Naidu SS; Smedira NG; Cremer PC; Schaff H; McErlean E; Sewell C; Li W; Sterling L; Lampl K; Edelberg JM; Sehnert AJ; Nissen SE
J Am Coll Cardiol; 2022 Jul; 80(2):95-108. PubMed ID: 35798455
[TBL] [Abstract][Full Text] [Related]
10. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Spertus JA; Fine JT; Elliott P; Ho CY; Olivotto I; Saberi S; Li W; Dolan C; Reaney M; Sehnert AJ; Jacoby D
Lancet; 2021 Jun; 397(10293):2467-2475. PubMed ID: 34004177
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy.
Ho CY; Mealiffe ME; Bach RG; Bhattacharya M; Choudhury L; Edelberg JM; Hegde SM; Jacoby D; Lakdawala NK; Lester SJ; Ma Y; Marian AJ; Nagueh SF; Owens A; Rader F; Saberi S; Sehnert AJ; Sherrid MV; Solomon SD; Wang A; Wever-Pinzon O; Wong TC; Heitner SB
J Am Coll Cardiol; 2020 Jun; 75(21):2649-2660. PubMed ID: 32466879
[TBL] [Abstract][Full Text] [Related]
12. Mavacamten: A Novel Agent for Hypertrophic Cardiomyopathy.
Chase Cole J; Benvie SF; DeLosSantos M
Clin Ther; 2024 Apr; 46(4):368-373. PubMed ID: 38508915
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Mavacamten in the Treatment of Hypertrophic Cardiomyopathy: A Systematic Review.
Bishev D; Fabara S; Loseke I; Alok A; Al-Ani H; Bazikian Y
Heart Lung Circ; 2023 Sep; 32(9):1049-1056. PubMed ID: 37453852
[TBL] [Abstract][Full Text] [Related]
14. An evaluation of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults.
Dong T; Nissen S; Ospina S; Desai MY
Expert Rev Cardiovasc Ther; 2023 Jan; 21(1):5-13. PubMed ID: 36522857
[TBL] [Abstract][Full Text] [Related]
15. Study design and rationale of EXPLORER-CN: a phase III, randomised, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of mavacamten in Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy.
Tian Z; Wang F; Jin W; Zhang Q; Zhou J; Yang P; Wang G; Hsu P; Sun J; Zhang S; Han Y
BMJ Open; 2023 Jun; 13(6):e071473. PubMed ID: 37336533
[TBL] [Abstract][Full Text] [Related]
16. Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: The EXPLORER-CN Randomized Clinical Trial.
Tian Z; Li L; Li X; Wang J; Zhang Q; Li Z; Peng D; Yang P; Ma W; Wang F; Jin W; Cheng X; Sun J; Fu Y; Lyu C; Zhang S
JAMA Cardiol; 2023 Oct; 8(10):957-965. PubMed ID: 37639259
[TBL] [Abstract][Full Text] [Related]
17. Projecting the Long-term Clinical Value of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy in the United States: An Assessment of Net Health Benefit.
Desai N; Xie J; Wang Y; Sutton MB; Whang J; Fine JT; Garrison LP
Clin Ther; 2022 Jan; 44(1):52-66.e2. PubMed ID: 34911641
[TBL] [Abstract][Full Text] [Related]
18. [Mavacamten (Camzyos ®) : first myosin modulator for obstructive hypertrophic cardiomyopathy treatment].
Lancellotti P; de Marneffe N; Scheen A
Rev Med Liege; 2024 Feb; 79(2):120-128. PubMed ID: 38356430
[TBL] [Abstract][Full Text] [Related]
19. Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results From the MAVA-LTE Study, EXPLORER-LTE Cohort.
Rader F; Oręziak A; Choudhury L; Saberi S; Fermin D; Wheeler MT; Abraham TP; Garcia-Pavia P; Zwas DR; Masri A; Owens A; Hegde SM; Seidler T; Fox S; Balaratnam G; Sehnert AJ; Olivotto I
JACC Heart Fail; 2024 Jan; 12(1):164-177. PubMed ID: 38176782
[TBL] [Abstract][Full Text] [Related]
20. Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy.
Wheeler MT; Jacoby D; Elliott PM; Saberi S; Hegde SM; Lakdawala NK; Myers J; Sehnert AJ; Edelberg JM; Li W; Olivotto I
Eur J Heart Fail; 2023 Feb; 25(2):260-270. PubMed ID: 36404399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
